Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high‐risk men-Reference-Cited by-同舟云学术

Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high‐risk men

Published:2019-10-11 Issue:1 Volume:80 Page:51-56
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Assel Melissa J.¹,Ulmert Hans David²³⁴,Karnes R. Jeffery⁵,Boorjian Stephen A.⁵,Hillman David W.⁶,Vickers Andrew J.¹,Klee George G.⁷,Lilja Hans⁴⁸⁹⁴^ORCID

Affiliation:

1. Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer Center New York New York

2. Molecular Pharmacology ProgramMemorial Sloan Kettering Cancer Center New York New York

3. Department of Molecular and Medical PharmacologyDavid Geffen School of Medicine at University of California Los Angeles California

4. Department of Translational MedicineLund University Malmö Sweden

5. Department of UrologyMayo Clinic Rochester Minnesota

6. Biomedical Statistics and InformaticsMayo Clinic Rochester Minnesota

7. Mayo Clinic College of Medicine and ScienceMayo Clinic Rochester Minnesota

8. Department of Laboratory Medicine, Surgery, and MedicineMemorial Sloan Kettering Cancer Center New York New York

9. Nuffield Department of Surgical SciencesUniversity of Oxford Oxford UK

Funder

Institut National Du Cancer

Vetenskapsrådet

Prostate Cancer Foundation

Cancerfonden

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23916

Reference23 articles.

1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

2. Screening for Prostate Cancer

3. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

4. Prostate‐specific antigen in serum occurs predominantly in complex with alpha 1‐antichymotrypsin;Lilja H;Clin Chem,1991

5. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate‐specific antigen lacking an internal cleavage site at Lys145‐Lys146;Nurmikko P;Clin Chem,2001

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kallikrein and Kallikrein-Related Peptidases;Encyclopedia of Cell Biology;2023

2. Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer;European Urology Open Science;2022-11

3. Remodelling of the tumour microenvironment by the kallikrein-related peptidases;Nature Reviews Cancer;2022-01-31

4. PSA: role in screening and monitoring patients with prostate cancer;Cancer Biomarkers;2022

5. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine;European Urology Open Science;2021-08